TABLE OF CONTENTS 1 6.3 Our strategy 68 PERSONS RESPONSIBLE 9 6.4 Gene therapy in the eye: a well-validated approach 69 1.1 Name and Position of the Person Responsible for the Registration Document 10 6.5 Our lead product candidate: GS010 for the treatment of LHON 70 1.2 Certification of the Person Responsible for the Registration Document 10 6.6 Our second product candidate: GS030 for the treatment of photoreceptor degeneration 76 1.3 Name and position of the Person Responsible for Financial Information 10 6.7 Leveraging our platforms to address central nervous system disorders 82 6.8 Pharmaco-economics of blindness and 2 STATUTORY AUDITORS 11 visual impairment 82 2.1 Statutory Auditors 12 6.9 Manufacturing 83 2.2 Alternate Statutory Auditors 12 6.10 Sales and marketing 83 6.11 Competition 83 6.12 Government regulation 84 3 SELECTED FINANCIAL INFORMATION 13 3.1 Selected consolidated Financial Information 14 7 ORGANIZATIONAL CHART 101 4 RISK FACTORS 17 4.1 Risks related to our financial condition 8 PROPERTY, PLANT AND EQUIPMENT 103 and capital requirements 18 8.1 Significant existing or planned property, 4.2 Risks related to the discovery and development plant and equipment 104 of and obtaining regulatory approval 8.2 Environment and sustainable development 104 for our product candidates 20 4.3 Risks related to third parties 29 4.4 Risks related to manufacturing 32 9 OPERATING AND FINANCIAL REVIEW 111 4.5 Risks related to the commercialization 9.1 Overview 113 of our product candidates 34 Risks related to our business operations 9.2 Financial operations overview 114 4.6 37 4.7 Risks related to finances and taxation 43 9.3 Results of operations 119 4.8 Legal risks and risks related to our intellectual property 44 10 CAPITAL RESOURCES 123 4.9 Market risks 53 10.1 Overview 124 4.10 Insurance and risk management 54 4.11Internal control and risk management procedures 58 10.2 Analysis of cash flow 124 4.12Financial risk related to climate change 59 10.3 Funding sources 124 10.4 Principal uses of cash 126 5 INFORMATION ABOUT THE ISSUER 61 11 RESEARCH AND DEVELOPMENT, 5.1 History and development 62 PATENTS AND LICENSES 129 5.2 Investments 63 11.1 Overview 130 11.2 Research and development expenditures 130 6 BUSINESS OVERVIEW 65 11.3 Medical and scientific committee 131 6.1 Overview 66 11.4 Collaboration, partnership and related agreements 132 6.2 Our product development pipeline 68 11.5 Intellectual property 134 6 – GENSIGHT BIOLOGICS – 2017 Registration Document